Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
I-MED Pharma’s products are commercially available globally for the diagnosis and management of dry eye disease. The company has pioneered viscoadaptive artificial tears with superior hyaluronan content, IRPL® device technology for meibomian gland dysfunction, diagnostic tools like the I-PEN®, ocular hygiene cleansers such as I-LID ’N LASH®, nutritional supplements including omega‑3s, punctum plugs, ointments like I‑DEFENCE®, and therapeutic accessories. Their solutions are used by ophthalmologists, optometrists, veterinarians, and patients worldwide.[1][2][7] No clinical trial results are published; products are marketed based on innovation in formulation/device design.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on I-MED Pharma.